Andamento 4523.T · Eisai Co., Ltd.
Cosa dice MarketSider oggi
Chi è Eisai Co., Ltd.
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Valutazione
Redditività
Crescita
Solidità Finanziaria
Dividendi
Cosa ne pensano gli analisti
Approfondisci i fondamentali
Analisi tecnica AI — 01 settembre 2026
RSI (14) — Momentum negativo35▾
MACD — Momentum rialzista forte57.61▾
Performance oggi — Invariato+0.40%▾
Volume — Volume basso672K▾
Sentiment AI notizie — Neutro0▾
Continua a imparare
Titoli correlati — Farmaceutico
18 in evidenza ora (selezione per movimento) · 48 nel settore
Ultime notizie su Eisai Co., Ltd.
Nessuna notizia recente su Eisai Co., Ltd.
Le notizie vengono aggiornate ogni 2 ore dalla pipeline AI.
Vai alle ultime notizieAnalisi approfondita su Eisai Co., Ltd.: target price, rischi, opportunità e confronto competitor.